51.54
+2.40%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About GlaxoSmithKline PLC ADR
Its shares trade under the ticker GSK. It has been listed since 9 July 1986. In the fiscal year to 31 December 2025, it reported revenue of $32.67bn and net income of $5.72bn. At that date it held total assets of $61.01bn and shareholders' equity of $16.35bn.
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 9 Jul 1986
- Employees
- 94,066
- Website
- gsk.com ↗
- Head office
- 79 NEW OXFORD STREET, LONDON, WC1A 1DG
- Incorporated in
- X0
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- GSK's vaccines cover Shingles, Meningitis, and RSV for global health protection.
- GSK's specialty medicines address oncology, respiratory, and inflammatory diseases with targeted therapies.
- GSK's general medicines treat asthma, COPD, and bacterial infections across multiple markets.
Weaknesses
- GSK's R&D segment focuses on oral small molecule therapies for unmet needs in oncology.
- GSK's Commercial Operations segment serves the UK, US, and international markets.
- GSK's employee count of 94,066 supports global operations but may increase costs.
Opportunities
- GSK's collaboration in oncology and inflammatory diseases offers new market potential.
- GSK's vaccines for HPV and Rotavirus target growing global health initiatives.
- GSK's respiratory/immunology segment aligns with increasing demand for respiratory treatments.
Threats
- GSK's focus on specialty medicines may face competition in oncology markets.
- GSK's vaccine portfolio includes diseases like Meningitis and RSV with high regulatory scrutiny.
- GSK's general medicines segment faces pricing pressures in asthma and COPD treatments.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.